2010
Elevated expression of MCP-1, IL-2 and PTPR-N in basal ganglia of Tourette syndrome cases
Morer A, Chae W, Henegariu O, Bothwell AL, Leckman JF, Kawikova I. Elevated expression of MCP-1, IL-2 and PTPR-N in basal ganglia of Tourette syndrome cases. Brain Behavior And Immunity 2010, 24: 1069-1073. PMID: 20193755, DOI: 10.1016/j.bbi.2010.02.007.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAutopsyBasal GangliaChemokine CCL2FemaleHumansInterferon-gammaInterleukin-1betaInterleukin-2Leukocyte Common AntigensMaleMiddle AgedPolymerase Chain ReactionReceptor-Like Protein Tyrosine Phosphatases, Class 2Receptor-Like Protein Tyrosine Phosphatases, Class 8RecoverinRNATourette SyndromeConceptsMCP-1IL-2Tourette syndromePost-mortem specimenBasal gangliaElevated expressionPost-infectious autoimmunityAdult TS patientsChronic inflammatory processEvidence of inflammationBasal ganglia areaInterleukin-1 βCentral nervous systemChemotactic factor-1TS casesReverse transcription-polymerase chain reaction analysisTranscription-polymerase chain reaction analysisReal-time reverse transcription-polymerase chain reaction analysisBrain tissue sectionsInflammatory factorsControl subjectsGanglia areaInflammatory processInterleukin-2TS patients
2005
Increased serum levels of interleukin-12 and tumor necrosis factor-alpha in Tourette’s syndrome
Leckman JF, Katsovich L, Kawikova I, Lin H, Zhang H, Krönig H, Morshed S, Parveen S, Grantz H, Lombroso PJ, King RA. Increased serum levels of interleukin-12 and tumor necrosis factor-alpha in Tourette’s syndrome. Biological Psychiatry 2005, 57: 667-673. PMID: 15780855, DOI: 10.1016/j.biopsych.2004.12.004.Peer-Reviewed Original ResearchConceptsEarly-onset obsessive-compulsive disorderObsessive-compulsive disorderSymptom exacerbationInterleukin-12Control subjectsImmune responseTourette syndromeTumor necrosis factor-alpha concentrationsNecrosis factor-alpha concentrationsAge-matched control subjectsInvolvement of innateLocal cytokine synthesisT cell immunityHumoral immune responseCentral nervous systemInnate immune responseLongitudinal studyProspective longitudinal studyT cell activationCell immunitySerum levelsPediatric populationCommon infectionsSerum concentrationsInflammatory process
1989
Plasma debrisoquin levels in the assessment of reduction of plasma homovanillic acid. The debrisoquin method.
Riddle MA, Jatlow PI, Anderson GM, Cho SC, Hardin MT, Cohen DJ, Leckman JF. Plasma debrisoquin levels in the assessment of reduction of plasma homovanillic acid. The debrisoquin method. Neuropsychopharmacology 1989, 2: 123-9. PMID: 2742727, DOI: 10.1016/0893-133x(89)90015-8.Peer-Reviewed Original ResearchConceptsCentral nervous systemPeripheral HVA productionDebrisoquin sulfatePHVA levelsHomovanillic acidPlasma homovanillic acidCerebrospinal fluid samplesAssessment of reductionDopamine metabolismPlasma concentrationsNervous systemFluid samplesSubstantial inhibitionHVACN metabolismDoseComplete inhibitionDopamineSubjectsInhibitionMetabolismDebrisoquinLevelsPHVA